A Phase III, Randomised, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Once-Daily Orally Administered ZD4054 10 mg in Non-Metastatic Hormone-Resistant Prostate Cancer Patients.

Trial Profile

A Phase III, Randomised, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Once-Daily Orally Administered ZD4054 10 mg in Non-Metastatic Hormone-Resistant Prostate Cancer Patients.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Zibotentan (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ENTHUSE-M0
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Apr 2013 Planned number of patients changed from 1507 to 2496 as reported by German Clinical Trials Register.
    • 31 May 2012 Actual end date May 2011 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top